AZITHROMYCIN POWDER FOR SOLUTION
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
14-01-2014
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
AZITHROMYCIN
Tilgjengelig fra:
DOMINION PHARMACAL
ATC-kode:
J01FA10
INN (International Name):
AZITHROMYCIN
Dosering :
200MG
Legemiddelform:
POWDER FOR SOLUTION
Sammensetning:
AZITHROMYCIN 200MG
Administreringsrute:
ORAL
Enheter i pakken:
15/22.5ML
Resept typen:
Prescription
Terapeutisk område:
OTHER MACROLIDES
Produkt oppsummering:
Active ingredient group (AIG) number: 0126072003; AHFS:
Autorisasjon status:
CANCELLED PRE MARKET
Autorisasjon dato:
2019-06-17
Preparatomtale
PRODUCT MONOGRAPH
PR
AZITHROMYCIN
Azithromycin dihydrate
(Powder for Oral Suspension 100 mg azithromycin/5 mL and 200 mg
azithromycin/5 mL) USP
Antibacterial Agent
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
1-888-550-6060
Date of Preparation:
December 17, 2013
Submission Control No: 170490
_ _
AZITHROMYCIN_ Product Monograph _
_Page_
_ _
_2 of 69_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
5
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
10
DRUG INTERACTIONS
.........................................................................................................
17
DOSAGE AND ADMINISTRATION
.....................................................................................
21
OVERDOSAGE
........................................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
26
STORAGE AND STABILITY
.................................................................................................
30
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 30
PART II: SCIENTIFIC INFORMATION
...............................................................................
31
PHARMACEUTICAL INFORMATION
.................................................................................
31
CLINICAL TRIALS
.
Les hele dokumentet
